KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Enterprise Value (2016 - 2026)

Bristol Myers Squibb has reported Enterprise Value over the past 18 years, most recently at -$10.5 billion for Q1 2026.

  • Quarterly Enterprise Value rose 10.84% to -$10.5 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$10.5 billion through Mar 2026, up 10.84% year-over-year, with the annual reading at -$10.6 billion for FY2025, 1.54% up from the prior year.
  • Enterprise Value was -$10.5 billion for Q1 2026 at Bristol Myers Squibb, up from -$10.6 billion in the prior quarter.
  • Over five years, Enterprise Value peaked at -$6.6 billion in Q2 2024 and troughed at -$16.5 billion in Q3 2025.
  • The 5-year median for Enterprise Value is -$10.5 billion (2026), against an average of -$10.7 billion.
  • Year-over-year, Enterprise Value soared 45.61% in 2022 and then crashed 105.32% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$9.2 billion in 2022, then crashed by 32.94% to -$12.2 billion in 2023, then increased by 11.61% to -$10.8 billion in 2024, then increased by 1.54% to -$10.6 billion in 2025, then grew by 1.77% to -$10.5 billion in 2026.
  • Per Business Quant, the three most recent readings for BMY's Enterprise Value are -$10.5 billion (Q1 2026), -$10.6 billion (Q4 2025), and -$16.5 billion (Q3 2025).